NCT05115292View on ClinicalTrials.gov

A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

October 20, 2024

Study Completion Date

October 20, 2025

Conditions
Advanced Solid Tumor or Lymphoma
Interventions
BIOLOGICAL

BJ-005

dosed with intravenous infusion

Trial Locations (6)

28078

Carolina BioOncology, Huntersville

32224

Mayo Clinic - Florida, Jacksonville

34952

Hematology/Oncology Assoc. of the Treasure Coast, Port Saint Lucie

55905

Mayo Clinic - Rochester, Rochester

78758

Next Oncology, Austin

85054

Mayo Clinic - Phoenix, Phoenix

Sponsors
All Listed Sponsors
lead

BJ Bioscience, Inc.

INDUSTRY

NCT05115292 - A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma | Biotech Hunter | Biotech Hunter